The value of supplemental prone imaging in low-dose CT lung cancer screening. A technical note

Submitted: October 29, 2021
Accepted: March 8, 2022
Published: March 14, 2022
Abstract Views: 887
PDF: 362
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.


This technical note presents our experience with the additional prone examination of patients during low dose CT lung cancer screening. The prone examination adds only a minor amount of radiation and time to the study and can reduce false positive findings that are gravity-dependent.



PlumX Metrics


Download data is not yet available.


The National Lung Screening Trial Research Team: Reduced lung-cancer mortality with low-dose computed tomography screening. N Engl J Med 2011;365:395-409. DOI:
De Koning HJ, van der Aalst CM, de Jong PA, et al. Reduced lung-cancer mortality with volume CT scanning in a randomized trial. N Engl J Med 2020;382:503-13. DOI:
Ebell MH, Bentivegna M, Hulme C. Cancer-specific mortality, all-cause mortality and overdiagnosis in lung cancer screening trials: a meta-analysis. Ann Fam Med 2020;18:545-52. DOI:
Kissinger LS, Anderson C, Kim J, et al. Implementation of lung cancer screening in the veterans health administration. J AMA Intern Med 2017;177:399-406.
Chung JH, Richards JC, Koelsch TL, et al. Screening for lung cancer: Incidental pulmonary parenchymal findings. AJR Am J Roentgenol 2018;210:503-13. DOI:
Hata A, Schiebler ML, Lynch DA, Hatabu H. Interstitial lung abnormalities: State of the art. Radiology 2021;301:19-34. DOI:

How to Cite

Stark, Paul, and Eric Y. Chang. 2022. “The Value of Supplemental Prone Imaging in Low-Dose CT Lung Cancer Screening. A Technical Note”. Monaldi Archives for Chest Disease 92 (4).